Novo Nordisk A/S (ADR) (NYSE:NVO)

CAPS Rating: 4 out of 5

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Recs

1
Player Avatar Meeussen (< 20) Submitted: 5/17/2011 11:01:56 AM : Outperform Start Price: $120.71 NVO Score: +16.91

Victoza

Featured Broker Partners


Advertisement